The Usefulness of Plasma Thrombin-Cleaved Osteopontin Level as a Novel Biomarker of the Acute Ischemic Stroke

The Usefulness of Plasma Thrombin-Cleaved Osteopontin Level as a Novel Biomarker of the Acute Ischemic Stroke - Acute Ischemic Stroke and Plasma Thrombin-Cleaved Osteopontin Level

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020183

Enrollment

100

Registered

2015-12-14

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic brain attack

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute ischemic brain attack admitted within the first 24 hours after symptom onset

Exclusion criteria

Exclusion criteria: Patients with intracranial hemorrhage, known inflammatory or malignant disease, abnormal coagulant disease, and/or cardiovascular operation within the previous 6 months

Design outcomes

Primary

Measure	Time frame
We evaluated the utility of plasma thrombin cleaved osteopontin N-terminal level as a diagnostic biomarkers of the ischemic stroke atherothrombotic subtype.	—

Countries

Japan

Contacts

Public ContactMie Kurata

Ehime University Graduate School of Mdicine Analytical Pathology

miekrt@m.ehime-u.ac.jp0899605977

Outcome results